Key Highlights
- Kinney Horn joins Immunome as Chief Business Officer, bringing vast experience in biotechnology business development.
- Previous roles include CBO of Olema Oncology and positions at Genentech, enhancing his strategic partnership expertise.
- Immunome now enters clinical stage with new assets, aiming to expand and enhance its cancer therapy portfolio.
Source: Business Wire
Notable Quotes
- “Immunome is excited to welcome Kinney to our executive team as we advance our broad pipeline of targeted therapies,” – Clay Siegall, PhD, President and CEO at Immunome
- “I am thrilled to join Immunome at such a transformative time. The opportunity to drive strategic business initiatives and expand Immunome’s strong portfolio is incredibly compelling – Kinney Horn, newly appointed CBO at Immunome
SoHC's Take
The appointment of Kinney Horn as Chief Business Officer of Immunome marks a significant step in the company’s strategy to fortify its leadership amidst its transition to a clinical stage. Horn’s impressive track record in securing strategic partnerships and funding in the biotech field is anticipated to drive Immunome’s ambitions in expanding its portfolio of innovative cancer therapies. His experience aligns perfectly with Immunome’s objectives, potentially catalyzing the company’s growth and enhancing its developmental capabilities. This strategic hire underscores Immunome’s commitment to advancing its mission of developing groundbreaking cancer treatments.
